Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Alzheimers Dement ; 11(8): 994-1004, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25849033

ABSTRACT

INTRODUCTION: Down syndrome (DS) is associated with amyloid b (Ab) deposition. METHODS: We characterized imaging measurements of regional fibrillar Ab burden, cerebral metabolic rate for glucose (rCMRgl), gray matter volumes (rGMVs), and age associations in 5 DS with dementia (DS/AD1), 12 DS without dementia (DS/AD2), and 9 normal controls (NCs). RESULTS: There were significant group differences in mean standard uptake value ratios (SUVRs) for florbetapir with DS/AD1 having the highest, followed by DS/AD2, followed by NC. For [18F]-fluorodeoxyglucose positron emission tomography, posterior cingulate rCMRgl in DS/AD1 was significantly reduced compared with DS/AD2 and NC. For volumetric magnetic resonance imaging (vMRI), hippocampal volumes were significantly reduced for the DS/AD1 compared with DS/AD2 and NC. Age-related SUVR increases and rCMRgl reductions were greater in DS participants than in NCs. DISCUSSION: DS is associated with fibrillar Ab, rCMRgl, and rGMV alterations in the dementia stage and before the presence of clinical decline. This study provides a foundation for the studies needed to inform treatment and prevention in DS.


Subject(s)
Aniline Compounds/metabolism , Brain/diagnostic imaging , Brain/pathology , Down Syndrome/pathology , Ethylene Glycols/metabolism , Fluorodeoxyglucose F18/metabolism , Magnetic Resonance Imaging , Positron-Emission Tomography , Adult , Alzheimer Disease/complications , Down Syndrome/complications , Emergency Services, Psychiatric , Female , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Neuropsychological Tests
2.
Alzheimers Dement ; 10(1): 93-8, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23562429

ABSTRACT

BACKGROUND: It is unclear whether self- or informant-based subjective cognition better distinguishes emotional factors from early-stage Alzheimer's disease (AD). METHODS: Healthy members (n = 447) of the Arizona apolipoprotein E (APOE) cohort and their informants completed the self and informant paired Multidimensional Assessment of Neurodegenerative Symptoms questionnaire (MANS). RESULTS: Decline on the MANS was endorsed by 30.6% of members and 26.2% of informants. Self- and informant-based decliners had higher scores of psychological distress and slightly lower cognitive scores than nondecliners. Over the next 6.7 years, 20 developed mild cognitive impairment (MCI). Converters were older at entry than nonconverters (63.8 [7.0] vs 58.8 [7.3] years, P = .003), 85% were APOE ε4 carriers (P < .0001), and they self-endorsed decline earlier than informants (58.9 [39.2] vs 28.0 [40.4] months before MCI; P = .002). CONCLUSIONS: Self- and informant-based subjective decline correlated with greater psychological distress and slightly lower cognitive performance. Those with incident MCI generally self-endorsed decline earlier than informants.


Subject(s)
Cognition Disorders/diagnosis , Cognition Disorders/psychology , Self Report , Acoustic Stimulation , Aged , Apolipoproteins E/genetics , Cohort Studies , Executive Function , Female , Humans , Language Disorders/etiology , Male , Middle Aged , Neurologic Examination , Neuropsychological Tests , Psychomotor Performance , Severity of Illness Index , Space Perception/physiology , Surveys and Questionnaires , Verbal Learning
3.
PLoS One ; 8(6): e67163, 2013.
Article in English | MEDLINE | ID: mdl-23840615

ABSTRACT

BACKGROUND: We introduced a hypometabolic convergence index (HCI) to characterize in a single measurement the extent to which a person's fluorodeoxyglucose positron emission tomogram (FDG PET) corresponds to that in Alzheimer's disease (AD). Apolipoprotein E ε4 (APOE ε4) gene dose is associated with three levels of risk for late-onset AD. We explored the association between gene dose and HCI in cognitively normal ε4 homozygotes, heterozygotes, and non-carriers. METHODS: An algorithm was used to characterize and compare AD-related HCIs in cognitively normal individuals, including 36 ε4 homozygotes, 46 heterozygotes, and 78 non-carriers. RESULTS: These three groups differed significantly in their HCIs (ANOVA, p = 0.004), and there was a significant association between HCIs and gene dose (linear trend, p = 0.001). CONCLUSIONS: The HCI is associated with three levels of genetic risk for late-onset AD. This supports the possibility of using a single FDG PET measurement to help in the preclinical detection and tracking of AD.


Subject(s)
Alzheimer Disease/genetics , Apolipoprotein E4/genetics , Gene Dosage , Age of Onset , Alzheimer Disease/diagnosis , Alzheimer Disease/epidemiology , Female , Genetic Predisposition to Disease/genetics , Humans , Male , Middle Aged , Positron-Emission Tomography
4.
Neuroimage ; 60(4): 2316-22, 2012 May 01.
Article in English | MEDLINE | ID: mdl-22348880

ABSTRACT

We previously introduced a voxel-based, multi-modal application of the partial least square algorithm (MMPLS) to characterize the linkage between patterns in a person's complementary complex datasets without the need to correct for multiple regional comparisons. Here we used it to demonstrate a strong correlation between MMPLS scores to characterize the linkage between the covarying patterns of fluorodeoxyglucose positron emission tomography (FDG PET) measurements of regional glucose metabolism and magnetic resonance imaging (MRI) measurements of regional gray matter associated with apolipoprotein E (APOE) ε4 gene dose (i.e., three levels of genetic risk for late-onset Alzheimer's disease (AD)) in cognitively normal, late-middle-aged persons. Coregistered and spatially normalized FDG PET and MRI images from 70% of the subjects (27 ε4 homozygotes, 36 ε4 heterozygotes and 67 ε4 non-carriers) were used in a hypothesis-generating MMPLS analysis to characterize the covarying pattern of regional gray matter volume and cerebral glucose metabolism most strongly correlated with APOE-ε4 gene dose. Coregistered and spatially normalized FDG PET and MRI images from the remaining 30% of the subjects were used in a hypothesis-testing MMPLS analysis to generate FDG PET-MRI gray matter MMPLS scores blind to their APOE genotype and characterize their relationship to APOE-ε4 gene dose. The hypothesis-generating analysis revealed covarying regional gray matter volume and cerebral glucose metabolism patterns that resembled those in traditional univariate analyses of AD and APOE-ε4 gene dose and PET-MRI scores that were strongly correlated with APOE-ε4 gene dose (p<1 × 10(-16)). The hypothesis-testing analysis results showed strong correlations between FDG PET-MRI gray matter scores and APOE-ε4 gene dose (p = 8.7 × 10(-4)). Our findings support the possibility of using the MMPLS to analyze complementary datasets from the same person in the presymptomatic detection and tracking of AD.


Subject(s)
Alzheimer Disease/diagnostic imaging , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Apolipoprotein E4/genetics , Gene Dosage , Magnetic Resonance Imaging , Positron-Emission Tomography , Algorithms , Brain/diagnostic imaging , Female , Fluorodeoxyglucose F18 , Glucose/metabolism , Humans , Image Interpretation, Computer-Assisted , Least-Squares Analysis , Male , Middle Aged , Radiopharmaceuticals , Risk Factors
5.
J Pediatr Hematol Oncol ; 33(5): 369-73, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21602725

ABSTRACT

BACKGROUND: Diffuse intrinsic brainstem gliomas (DIBSGs) in children remain difficult tumors to treat and have a very poor prognosis. Intensifying both chemotherapy and radiation programs have been attempted without success. Positron emission tomography (PET) has been used to differentiate benign from malignant tumors and may predict outcome. OBJECTIVES: To determine whether PET can characterize a specific metabolic pattern of DIBSGs and correlate this with patient survival. METHODS: We conducted a retrospective review of patients with DIBSGs and PET scans at diagnosis. Data for ¹8[F] fluorodeoxyglucose (FDG) and ¹¹C-methionine (CMET) PET scans were collected. Treatment and survival were reviewed. RESULTS: We identified 30 patients with DIBSGs, 25 of whom had FDG and/or CMET PET scans. Scans showed both focal and generalized metabolic activity, and the patterns showed no correlation with survival. Patients with both FDG and CMET positive scans had a mean survival of 380 days, whereas those negative for both isotopes had a mean survival of 446 days. CONCLUSIONS: There was no specific PET pattern identified in this DIBSG cohort but a trend toward improved survival was noted with absence of FDG and CMET metabolism. Metabolically active areas may suggest potential sites for biopsy. We believe that biopsy is essential for improving therapy for this patient population.


Subject(s)
Brain Stem Neoplasms/diagnostic imaging , Glioma/diagnostic imaging , Positron-Emission Tomography/methods , Adolescent , Brain Stem Neoplasms/mortality , Brain Stem Neoplasms/therapy , Child , Child, Preschool , Female , Fluorodeoxyglucose F18 , Glioma/mortality , Glioma/therapy , Humans , Male , Methionine , Radiopharmaceuticals , Retrospective Studies
6.
Neuroimage ; 56(1): 52-60, 2011 May 01.
Article in English | MEDLINE | ID: mdl-21276856

ABSTRACT

This article introduces a hypometabolic convergence index (HCI) for the assessment of Alzheimer's disease (AD); compares it to other biological, cognitive and clinical measures; and demonstrates its promise to predict clinical decline in mild cognitive impairment (MCI) patients using data from the AD Neuroimaging Initiative (ADNI). The HCI is intended to reflect in a single measurement the extent to which the pattern and magnitude of cerebral hypometabolism in an individual's fluorodeoxyglucose positron emission tomography (FDG-PET) image correspond to that in probable AD patients, and is generated using a fully automated voxel-based image-analysis algorithm. HCIs, magnetic resonance imaging (MRI) hippocampal volume measurements, cerebrospinal fluid (CSF) assays, memory test scores, and clinical ratings were compared in 47 probable AD patients, 21 MCI patients who converted to probable AD within the next 18months, 76 MCI patients who did not, and 47 normal controls (NCs) in terms of their ability to characterize clinical disease severity and predict conversion rates from MCI to probable AD. HCIs were significantly different in the probable AD, MCI converter, MCI stable and NC groups (p=9e-17) and correlated with clinical disease severity. Using retrospectively characterized threshold criteria, MCI patients with either higher HCIs or smaller hippocampal volumes had the highest hazard ratios (HRs) for 18-month progression to probable AD (7.38 and 6.34, respectively), and those with both had an even higher HR (36.72). In conclusion, the HCI, alone or in combination with certain other biomarker measurements, has the potential to help characterize AD and predict subsequent rates of clinical decline. More generally, our conversion index strategy could be applied to a range of imaging modalities and voxel-based image-analysis algorithms.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Brain Mapping/methods , Cognition Disorders/metabolism , Cognition Disorders/pathology , Image Interpretation, Computer-Assisted/methods , Aged , Aged, 80 and over , Algorithms , Disease Progression , Female , Hippocampus/metabolism , Hippocampus/pathology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Positron-Emission Tomography
7.
J Alzheimers Dis ; 22(4): 1241-56, 2010.
Article in English | MEDLINE | ID: mdl-20930300

ABSTRACT

Here we report the first multi-center clinical trial in Alzheimer's disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months treatment with the PPARγ agonist Rosiglitazone XR versus placebo in 80 mild to moderate AD patients. Secondary objectives included testing for reduction in the progression of brain atrophy and improvement in cognition. Active treatment was associated with a sustained but not statistically significant trend from the first month for higher mean values in Kiindex and CMRgluindex, novel quantitative indices related to the combined forward rate constant for [18F]FDG uptake and to the rate of cerebral glucose utilization, respectively. However, neither these nor another analytical approach recently validated using data from the Alzheimer's Disease Neuroimaging Initiative indicated that active treatment decreased the progression of decline in brain glucose metabolism. Rates of brain atrophy were similar between active and placebo groups and measures of cognition also did not suggest clear group differences. Our study demonstrates the feasibility of using [18F]FDG-PET as part of a multi-center therapeutics trial. It suggests that Rosiglitazone is associated with an early increase in whole brain glucose metabolism, but not with any biological or clinical evidence for slowing progression over a 1 year follow up in the symptomatic stages of AD.


Subject(s)
Alzheimer Disease/diagnostic imaging , Alzheimer Disease/drug therapy , Brain/drug effects , Brain/diagnostic imaging , Glucose/metabolism , Thiazolidinediones/therapeutic use , Aged , Aged, 80 and over , Alzheimer Disease/metabolism , Brain/metabolism , Brain Mapping , Disease Progression , Double-Blind Method , Female , Fluorodeoxyglucose F18/metabolism , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Middle Aged , Positron-Emission Tomography , Rosiglitazone , Treatment Outcome
8.
J Neurosci Methods ; 192(2): 277-85, 2010 Oct 15.
Article in English | MEDLINE | ID: mdl-20678521

ABSTRACT

Fluorodeoxyglucose positron emission tomography (FDG-PET) studies report characteristic patterns of cerebral hypometabolism in probable Alzheimer's disease (pAD) and amnestic mild cognitive impairment (aMCI). This study aims to characterize the consistency of regional hypometabolism in pAD and aMCI patients enrolled in the AD neuroimaging initiative (ADNI) using statistical parametric mapping (SPM) and bootstrap resampling, and to compare bootstrap-based reliability index to the commonly used type-I error approach with or without correction for multiple comparisons. Batched SPM5 was run for each of 1000 bootstrap iterations to compare FDG-PET images from 74 pAD and 142 aMCI patients, respectively, to 82 normal controls. Maps of the hypometabolic voxels detected for at least a specific percentage of times over the 1000 runs were examined and compared to an overlap of the hypometabolic maps obtained from 3 randomly partitioned independent sub-datasets. The results from the bootstrap derived reliability of regional hypometabolism in the overall data set were similar to that observed in each of the three non-overlapping sub-sets using family-wise error. Strong but non-linear association was found between the bootstrap-based reliability index and the type-I error. For threshold p=0.0005, pAD was associated with extensive hypometabolic voxels in the posterior cingulate/precuneus and parietotemporal regions with reliability between 90% and 100%. Bootstrap analysis provides an alternative to the parametric family-wise error approach used to examine consistency of hypometabolic brain voxels in pAD and aMCI patients. These results provide a foundation for the use of bootstrap analysis characterize statistical ROIs or search regions in both cross-sectional and longitudinal FDG-PET studies. This approach offers promise in the early detection and tracking of AD, the evaluation of AD-modifying treatments, and other biologically or clinical important measurements using brain images and voxel-based data analysis techniques.


Subject(s)
Alzheimer Disease/diagnostic imaging , Amnesia/diagnostic imaging , Brain/diagnostic imaging , Cognition Disorders/diagnostic imaging , Positron-Emission Tomography/methods , Aged , Aged, 80 and over , Alzheimer Disease/metabolism , Amnesia/metabolism , Brain/metabolism , Brain Mapping/methods , Cognition Disorders/metabolism , Female , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Reproducibility of Results
9.
Alzheimers Dement ; 6(3): 221-9, 2010 May.
Article in English | MEDLINE | ID: mdl-20451870

ABSTRACT

BACKGROUND: This is a progress report of the Alzheimer's Disease Neuroimaging Initiative (ADNI) positron emission tomography (PET) Core. METHODS: The Core has supervised the acquisition, quality control, and analysis of longitudinal [(18)F]fluorodeoxyglucose PET (FDG-PET) data in approximately half of the ADNI cohort. In an "add on" study, approximately 100 subjects also underwent scanning with [(11)C] Pittsburgh compound B PET for amyloid imaging. The Core developed quality control procedures and standardized image acquisition by developing an imaging protocol that has been widely adopted in academic and pharmaceutical industry studies. Data processing provides users with scans that have identical orientation and resolution characteristics despite acquisition on multiple scanner models. The Core labs have used many different approaches to characterize differences between subject groups (Alzheimer's disease, mild cognitive impairment, controls), to examine longitudinal change over time in glucose metabolism and amyloid deposition, and to assess the use of FDG-PET as a potential outcome measure in clinical trials. RESULTS: ADNI data indicate that FDG-PET increases statistical power over traditional cognitive measures, might aid subject selection, and could substantially reduce the sample size in a clinical trial. Pittsburgh compound B PET data showed expected group differences, and identified subjects with significant annual increases in amyloid load across the subject groups. The next activities of the PET core in ADNI will entail developing standardized protocols for amyloid imaging using the [(18)F]-labeled amyloid imaging agent AV45, which can be delivered to virtually all ADNI sites. CONCLUSIONS: ADNI has demonstrated the feasibility and utility of multicenter PET studies and is helping to clarify the role of biomarkers in the study of aging and dementia.


Subject(s)
Alzheimer Disease/diagnostic imaging , Positron-Emission Tomography/methods , Aged , Aged, 80 and over , Amyloid/metabolism , Aniline Compounds , Brain Mapping , Cohort Studies , Female , Fluorodeoxyglucose F18 , Humans , Imaging, Three-Dimensional , Male , Retrospective Studies , Thiazoles
10.
Neuroimage ; 51(2): 654-64, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20202480

ABSTRACT

Alzheimer's disease (AD) is characterized by specific and progressive reductions in fluorodeoxyglucose positron emission tomography (FDG PET) measurements of the cerebral metabolic rate for glucose (CMRgl), some of which may precede the onset of symptoms. In this report, we describe twelve-month CMRgl declines in 69 probable AD patients, 154 amnestic mild cognitive impairment (MCI) patients, and 79 cognitively normal controls (NCs) from the AD Neuroimaging Initiative (ADNI) using statistical parametric mapping (SPM). We introduce the use of an empirically pre-defined statistical region-of-interest (sROI) to characterize CMRgl declines with optimal power and freedom from multiple comparisons, and we estimate the number of patients needed to characterize AD-slowing treatment effects in multi-center randomized clinical trials (RCTs). The AD and MCI groups each had significant twelve-month CMRgl declines bilaterally in posterior cingulate, medial and lateral parietal, medial and lateral temporal, frontal and occipital cortex, which were significantly greater than those in the NC group and correlated with measures of clinical decline. Using sROIs defined based on training sets of baseline and follow-up images to assess CMRgl declines in independent test sets from each patient group, we estimate the need for 66 AD patients or 217 MCI patients per treatment group to detect a 25% AD-slowing treatment effect in a twelve-month, multi-center RCT with 80% power and two-tailed alpha=0.05, roughly one-tenth the number of the patients needed to study MCI patients using clinical endpoints. Our findings support the use of FDG PET, brain-mapping algorithms and empirically pre-defined sROIs in RCTs of AD-slowing treatments.


Subject(s)
Alzheimer Disease/diagnostic imaging , Brain Mapping/methods , Brain/diagnostic imaging , Cognition Disorders/diagnostic imaging , Aged , Algorithms , Alzheimer Disease/pathology , Brain/pathology , Cognition Disorders/pathology , Disease Progression , Female , Humans , Longitudinal Studies , Male , Multicenter Studies as Topic , Positron-Emission Tomography , Randomized Controlled Trials as Topic , Research Design
11.
Neuroimage ; 45(4): 1107-16, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19349228

ABSTRACT

In mostly small single-center studies, Alzheimer's disease (AD) is associated with characteristic and progressive reductions in fluorodeoxyglucose positron emission tomography (PET) measurements of the regional cerebral metabolic rate for glucose (CMRgl). The AD Neuroimaging Initiative (ADNI) is acquiring FDG PET, volumetric magnetic resonance imaging, and other biomarker measurements in a large longitudinal multi-center study of initially mildly affected probable AD (pAD) patients, amnestic mild cognitive impairment (aMCI) patients, who are at increased AD risk, and cognitively normal controls (NC), and we are responsible for analyzing the PET images using statistical parametric mapping (SPM). Here we compare baseline CMRgl measurements from 74 pAD patients and 142 aMCI patients to those from 82 NC, we correlate CMRgl with categorical and continuous measures of clinical disease severity, and we compare apolipoprotein E (APOE) varepsilon4 carriers to non-carriers in each of these subject groups. In comparison with NC, the pAD and aMCI groups each had significantly lower CMRgl bilaterally in posterior cingulate, precuneus, parietotemporal and frontal cortex. Similar reductions were observed when categories of disease severity or lower Mini-Mental State Exam (MMSE) scores were correlated with lower CMRgl. However, when analyses were restricted to the pAD patients, lower MMSE scores were significantly correlated with lower left frontal and temporal CMRgl. These findings from a large, multi-site study support previous single-site findings, supports the characteristic pattern of baseline CMRgl reductions in AD and aMCI patients, as well as preferential anterior CMRgl reductions after the onset of AD dementia.


Subject(s)
Alzheimer Disease/diagnostic imaging , Cerebral Cortex/diagnostic imaging , Cognition Disorders/diagnostic imaging , Fluorodeoxyglucose F18 , Positron-Emission Tomography/methods , Aged , Female , Humans , Male , Middle Aged , Radiopharmaceuticals , Reference Values , Reproducibility of Results , Sensitivity and Specificity , Statistics as Topic
12.
Sleep ; 29(7): 927-33, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16895260

ABSTRACT

STUDY OBJECTIVES: To test the hypothesis that healthy adults reporting dream-enactment behavior (DEB+) have reduced cerebral metabolic rate for glucose (CMRgl) in regions preferentially affected in patients with dementia with Lewy bodies (DLB). DESIGN: Automated brain-mapping algorithms were used to compare regional fluorodeoxyglucose (FDG) positron emission tomography (PET) measurements from previously evaluated DEB cases and controls. SETTING: Tertiary-care academic medical centers. PARTICIPANTS: Seventeen cognitively normal patients with DEB+ and 17 control subjects (DEB-) who were individually matched for age (59 +/- 11 years), education level (16 +/- 4 years), sex (67% women), body mass index (26 +/- 4.8 kg/m2), first-degree relative with dementia (85%), and proportion of apolipoprotein E (APOE) e4 carriers (13 e4 carriers, 4 noncarriers). INTERVENTIONS: FDG-PET. MEASUREMENTS AND RESULTS: DEB was associated with significantly lower CMRgl in several brain regions known to be preferentially affected in both DLB and Alzheimer disease (parietal, temporal, and posterior cingulate cortexes) and in several other regions, including the anterior cingulate cortex (p < .001, uncorrected for multiple comparisons). The DEB-associated CMRgl reductions were significantly greater in the APOE e4 noncarriers than in the carriers. CONCLUSIONS: These preliminary findings suggest that cognitively normal persons with DEB have reduced CMRgl in brain regions known to be metabolically affected by DLB, supporting further study of DEB as a possible risk factor for the development of DLB.


Subject(s)
Brain/metabolism , Fluorodeoxyglucose F18/pharmacokinetics , Health Status , Positron-Emission Tomography , Radiopharmaceuticals , Sleep/physiology , Adult , Algorithms , Apolipoprotein E4 , Apolipoproteins E/metabolism , Brain Mapping , Female , Follow-Up Studies , Glucose/metabolism , Humans , Male , Middle Aged , Radiopharmaceuticals/pharmacokinetics , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...